School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
The First People's Hospital of Wenling, Wenling, 317500, Zhejiang, China.
BMC Pregnancy Childbirth. 2022 Mar 22;22(1):231. doi: 10.1186/s12884-022-04541-1.
Surfactant protein D (SP-D) is a critical component of the innate immune system intrinsically linked to energy metabolism. However, the relationship of SP-D gene polymorphisms and gestational diabetes mellitus (GDM) remains unclear. In this study, we analyzed SP-D gene polymorphisms in GDM patients and nondiabetic controls and then determined the association of SP-D gene polymorphisms with GDM.
We examined a common genetic polymorphism located in the SP-D coding region (rs721917, Met31Thr) in GDM patients (n = 147) and healthy pregnant controls (n = 97) by using a cleaved amplification polymorphism sequence-tagged sites (PCR-RFLP) technique. The level of SP-D protein in the serum of GDM patients and nondiabetic controls was determined by ELISA. The gene and allele frequencies of SP-D and their association with GDM as well as SP-D protein levels were analyzed and expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs).
We found that there was a significant association of the SP-D polymorphism (rs721917) with GDM. The SP-D (T/T) genotype was found in 11.6% and 21.6% of GDM patients and matched healthy controls, respectively (odds ratio, 0.473; 95% confidence interval, 0.235-0.952; P = 0.033), indicating that women with the (T/T) genotype had a lower prevalence of GDM (OR = 0.473). Women with the T/C genotype showed an increased risk of GDM (odds ratio, 2.440; 95% confidence interval, 1.162-5.123; P = 0.017). We did not observe corrections between glucose homeostasis markers and SP-D genotypes in women with GDM. Furthermore, serum SP-D levels were higher in GDM patients than in matched healthy controls.
This study found the first evidence that an SP-D gene polymorphism (rs721917) was associated with GDM, which may provide the basis for further study on how SP-D plays a regulatory role in GDM.
表面活性蛋白 D (SP-D) 是先天免疫系统的重要组成部分,与能量代谢密切相关。然而,SP-D 基因多态性与妊娠糖尿病 (GDM) 的关系尚不清楚。在这项研究中,我们分析了 GDM 患者和非糖尿病对照组中 SP-D 基因的多态性,然后确定了 SP-D 基因多态性与 GDM 的关系。
我们通过聚合酶链反应-限制性片段长度多态性 (PCR-RFLP) 技术检测了 GDM 患者 (n=147) 和健康孕妇对照组 (n=97) 中位于 SP-D 编码区的常见遗传多态性 (rs721917,Met31Thr)。采用 ELISA 法检测 GDM 患者和非糖尿病对照组血清中 SP-D 蛋白的水平。分析 SP-D 基因和等位基因频率及其与 GDM 的关系,并以比值比 (OR) 及其 95%置信区间 (95%CI) 表示。
我们发现 SP-D 多态性 (rs721917) 与 GDM 显著相关。GDM 患者中 SP-D(T/T)基因型的频率为 11.6%,匹配的健康对照组为 21.6% (OR,0.473;95%CI,0.235-0.952;P=0.033),表明 T/T 基因型女性 GDM 患病率较低 (OR=0.473)。携带 T/C 基因型的女性患 GDM 的风险增加 (OR,2.440;95%CI,1.162-5.123;P=0.017)。我们没有观察到 GDM 女性的血糖稳态标志物与 SP-D 基因型之间的相关性。此外,GDM 患者的血清 SP-D 水平高于匹配的健康对照组。
本研究首次发现 SP-D 基因多态性 (rs721917) 与 GDM 相关,这可能为进一步研究 SP-D 如何在 GDM 中发挥调节作用提供依据。